Here are four things to know.
1. Shingrix is a nonlive, recombinant subunit Shingles vaccine for adults age 50 and older.
2. The vaccine is administered intramuscularly in two doses.
3. In a recent Phase III clinical trial with more than 38,000 patients, Shingrix had a more than 90 percent efficacy against shingles for all age groups.
4. GlaxoSmithKline expects Shingrix to be available shortly, pending a recommendation from the CDC’s Advisory Committee on Immunization Practices.
More articles on supply chain:
Analysis: Biosimilar drugs could cut US healthcare spending by $54B
Health apps should be held to high regulatory scrutiny, researchers say
FDA: 50 medical devices at risk of shortages after Hurricane Maria
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
